Timothée Olivier, Medical Oncologist at the Oncology Division of Geneva University Hospital in Switzerland, shared an article on X:
“Our new work out in Translational Oncology, led by Sruthi Ranganathan again!!
A pure product from VKPrasadLab, Vinay Prasad.
FRESCO-2 is potentially problematic due to the suboptimal use of placebo, and due to the poor cost-effectiveness of fruquintinib.”
FRESCO–2 trial and fruquintinib: A clearer picture of the control arm.
Authors: Sruthi Ranganathan, Alyson Haslam, Timothée Olivier, Vinay Prasad.
You can read the full article on Journal of Translational Oncology.
More posts featuring Timothée Olivier.